Navigation Links
At Twelve Months Post-Launch, the Majority of Surveyed Oncologists Have Prescribed Xtandi to Their Docetaxel-Pretreated Metastatic Castrate-Resistant Prostate Cancer Patients

EXTON, Pa., Dec. 9, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, at 12 months following the U.S. launch of Medivation/Astellas Pharma's Xtandi for docetaxel-pretreated metastatic castrate-resistant prostate cancer (mCRPC), the majority of surveyed oncologists stated that they have prescribed Xtandi in clinical practice, whereas the majority of surveyed urologists indicated that they had not yet prescribed Xtandi. Of current non-prescribers who plan on prescribing Xtandi for docetaxel-pretreated mCRPC in the future, the majority of urologists and oncologists stated that they will prescribe Xtandi within the next six months.

(Logo: )

The third wave of the LaunchTrends® Xtandi (US) report series—fielded 12 months following the launch of Xtandi for docetaxel-pretreated mCRPC in the United States—finds that surveyed physicians indicated that the lack of steroid requirement and the efficacy profile of Xtandi are among its top perceived advantages compared with Johnson & Johnson/Janssen Biotech/Janssen-Cilag's Zytiga, a finding that is consistent with prior waves of research. Nearly one-quarter of surveyed physicians indicated that they perceive no disadvantage of Xtandi compared with Zytiga.

The report also finds that the majority of surveyed physicians stated that first-line use of Zytiga for the treatment of chemotherapy-naive mCRPC remains unchanged following the commercial availability of Xtandi in the docetaxel-pretreated mCRPC setting. According to surveyed oncologists, Zytiga is currently the first-line patient share leader for the treatment of chemotherapy-naive mCRPC and will remain so in six months' time.

"Up to half of surveyed physicians indicated that docetaxel-naive asymptomatic or minimally symptomatic mCRPC and docetaxel-naive symptomatic mCRPC are highly appropriate patient populations for Xtandi," said Decision Resources Group Senior Business Insights Analyst Khurram Nawaz, M.Sc. "If Xtandi is approved for the first-line, asymptomatic or minimally symptomatic mCRPC patient population, surveyed physicians stated that they would prescribe Xtandi to more than 40 percent of their patients in that setting."

LaunchTrends® Xtandi (US) is a three-wave syndicated report series designed to track the uptake of Xtandi following its launch for docetaxel-pretreated mCRPC at one month, six months and 12 months following Xtandi's commercial availability, based upon primary research with U.S. oncologists and urologists. LaunchTrends assess trial and use of new products, obstacles to use, reasons to use, typical patient types, line of therapy, product perceptions, promotional efforts/messages and product satisfaction. For this third wave of research, BioTrends surveyed 49 U.S. oncologists and 51 U.S. urologists, and conducted qualitative interviews with 10 U.S. oncologists and urologists in October 2013.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:
Decision Resources Group
Christopher Comfort


SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. InspireMDs MGuard Stent Shows Lower Mortality Rate in STEMI Patients at Twelve Months Compared to Control Group
2. One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs
3. LDM Group and Polyglot Systems Partnership Brings Easy-to-Understand Medication Instructions to Over Twelve Languages
4. ResMed Inc. Announces Record Financial Results For The Quarter And Twelve Months Ended June 30, 2012
5. International Isotopes Inc. Announces Third Quarter And Nine Months 2013 Financial Results
6. Skyline Medical Announces Results for Third Quarter and First Nine Months of 2013
7. China Biologic Reports Financial Results for the Third Quarter and First Nine Months of 2013
8. Surveyed Physicians Report that Invokana Captures a Small Percentage of Patient Share in the Type 2 Diabetes Drug Market, With Significant Increases Expected Six Months from Now
9. The Majority Of Oncologists Will Begin Using Biosimilar Monoclonal Antibodies Within 12 Months Of Launch
10. Tecfideras Patient Share at Three Months Postlaunch Surpasses That for Aubagio and Gilenya At the Same Stage of Their Launches
11. International Isotopes Inc. Announces Second Quarter and Six Months 2013 Financial Results
Post Your Comments:
(Date:11/30/2015)... and ST. LOUIS , Nov. ... (NASDAQ: ESRX ) today announced an early renewal ... which began in 1999, will now extend through at ... --> After evaluating pharmacy benefit manager capabilities during ... Express Scripts continues to offer the best health plan ...
(Date:11/30/2015)... Nov. 30, 2015 NHS Supply Chain ... TrueBeam™ machines from Varian Medical Systems (NYSE: ... to replace older machines and institute modern radiotherapy ... public hospitals. The order, placed in September, also ... for Varian,s RapidArc® and Eclipse™ software systems.    ...
(Date:11/30/2015)... , Nov. 30, 2015  Novartis will demonstrate the ... 57 th American Society of Hematology (ASH) Annual ... myelomas as well as supportive care, including key findings ... personalized cell therapies. The ASH Annual Meeting will be ... . Novartis Oncology . "We will be ...
Breaking Medicine Technology:
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... lecturer at a University of Delaware Accounting and Management of Information Systems course. ... solutions for mid-market businesses. Sommer will speak at before student in the Enterprise ...
(Date:11/30/2015)... Doylestown, PA (PRWEB) , ... November 30, 2015 , ... ... the 15th annual Regional Biotech Conference, organized by the Baruch S. Blumberg Institute. , ... than 100 of the area’s life science and biotechnology leaders for the conference, which ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... teams looking to maximize recovery through quality sleep. Tim DiFrancesco, training coach for ... a better night’s sleep. ChiliPad precisely regulates the surface temperature of each side ...
(Date:11/30/2015)... NJ (PRWEB) , ... November 30, 2015 , ... Dr. ... With three office locations, patients can visit Dr. Margulies to experience the best available ... to hold the title of "NJ Top Dentist"! , Orthodontics is the branch of ...
(Date:11/30/2015)... ... November 30, 2015 , ... The recently published 32nd ... System (NPDS) reveals that in 2014, someone called a poison center about every ... of which were human exposure cases. , The American Association of Poison Control ...
Breaking Medicine News(10 mins):